| Literature DB >> 31692746 |
Mohd Shahnawaz Khan1, Ranu Agrawal2, Mohammad Ubaidullah3, Md Imtaiyaz Hassan4, Nazia Tarannum2.
Abstract
An ecofriendly itinerary for the synthesis of newly substituted chromene-3-carboxamide derivatives was undertaken to avoid impurities, usage of toxic solvents, toxic catalyst, and having improved quantitative yields. The green synthesis involves the condensation of substituted salicylaldehyde with N-(substituted)phenyl malonic acid in the presence of a base catalyst, piperidine. All reported compounds were assessed for their antimicrobial activities which clearly suggested their therapeutic implications to address antimicrobial pathogenesis. The synthesized coumarin compounds were examined for their antimicrobial activity against 7 fungal strains and 2 bacterial strains at concentration 125-1000 μg/mL. In particular, the compounds 4 and 5 showed lower minimum inhibitory concentration value (125 μg/mL) against maximum microbial strains. Further, docking of all the synthesized compounds was performed with the enzymes lanosterol 14α-demethylase and glucosamine-6-phosphate synthase and a significant binding affinity was observed which supports in vivo antimicrobial study. In addition, the thermal analysis revealed good thermal stability of compounds up to 250 °C. The compounds showed abroad absorption spectrum between 280-550 nm establishing them to be good UV absorbers.Entities:
Keywords: Antimicrobial activity; Drug design and discovery; Green synthesis; Minimum inhibitory concentration; Molecular docking; Organic chemistry; Pharmaceutical chemistry; Substituted coumarin derivatives
Year: 2019 PMID: 31692746 PMCID: PMC6806407 DOI: 10.1016/j.heliyon.2019.e02615
Source DB: PubMed Journal: Heliyon ISSN: 2405-8440
Fig. 1Reaction scheme for the synthesis of coumarin compounds and their structure and yield % (where, R=(1); 6-Br, (2); 6-Cl, (3); 6-NO2, (4); 6,8-dibromo, (5); 6,8-dichloro, (6); 6-Cl, 8-NO2, (7); 6,8-NO2, (8); 6-Br, 8-NO2, (9); 6,8-diiodo, (10); 8-NO2).
Fig. 2Mechanistic approach for synthesized compounds (1–10).
Fig. 3UV-visible spectrum of (a) compounds (1–5) and (b) compounds (6–10).
Electronic absorption (UV λmax), emission wavelength (Emλmax), molar absorptivity coefficient (ε) and Stoke's shift of coumarin compounds (1–10).
| Compound | λmax (nm) | Molar Absorptivity Coefficient (ε) Lmol−1cm−1 | Emission Wavelength (nm) | Stoke's Shift (nm) |
|---|---|---|---|---|
| 1 | 438 | 107.14 | 475 | 160 |
| 2 | 375 | 317.46 | 425 | 110 |
| 3 | 425 | 48.18 | 525 | 210 |
| 4 | 430 | 41.66 | 575 | 260 |
| 5 | 380 | 344.82 | 560 | 245 |
| 6 | 495 | 196.42 | 570 | 255 |
| 7 | 355 | 418.18 | 525 | 210 |
| 8 | 425 | 196.07 | 525 | 210 |
| 9 | 420 | 48.78 | 415, 500 | 100,185 |
| 10 | 432 | 81.96 | 525 | 210 |
Fig. 4Fluorescence spectrum of (a) compounds (1–5) and (b) compounds (6–10).
Fig. 5Thermogravimetric analysis of synthesized Coumarin compounds1-7 and 9-10.
In vitro antimicrobial activity of target coumarin compounds (1–10).
| Test strains | (Coumarin compounds) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 500 | 500 | 500 | 1000 | 500 | 1000 | 750 | 750 | 1000 | 1000 | |
| >1000 | >1000 | 750 | 125 | 125 | 250 | 750 | >1000 | >1000 | 1000 | |
| 500 | 1000 | 250 | <125 | 125 | 500 | 250 | 750 | 750 | 250 | |
| 1000 | 1000 | 500 | 125 | <125 | 1000 | 750 | 1000 | 750 | 500 | |
| 1000 | 1000 | 250 | 250 | 1000 | 250 | 500 | 1000 | 1000 | 250 | |
| 500 | 750 | 500 | 750 | 750 | 500 | 750 | >1000 | 500 | 500 | |
| >1000 | 250 | 1000 | 1000 | 750 | 1000 | 1000 | 750 | 750 | 750 | |
| >1000 | >1000 | 500 | 250 | 250 | 250 | 500 | 750 | 750 | 250 | |
| 750 | 1000 | 250 | 250 | 250 | 250 | 1000 | 750 | 750 | 250 | |
In vitro antimicrobial activity of tested compounds in term of the zone of inhibition diameter (mm), Fluconazole and Ciprofloxacin are used as reference drugs.
| Compound number | Test strains | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Fungal strains | Bacterial strain | ||||||||
| 11 | 0 | 12 | 4 | 6 | 12 | 4 | 8 | 0 | |
| 11 | 0 | 4 | 6 | 6 | 8 | 14 | 7 | 0 | |
| 10 | 6 | 14 | 10 | 14 | 13 | 6 | 12 | 10 | |
| 8 | 16 | 27 | 18 | 14 | 8 | 6 | 12 | 12 | |
| 11 | 18 | 20 | 27 | 6 | 10 | 8 | 15 | 16 | |
| 6 | 14 | 12 | 6 | 14 | 10 | 6 | 10 | 12 | |
| 8 | 7 | 14 | 10 | 12 | 8 | 6 | 6 | 10 | |
| 8 | 0 | 8 | 6 | 4 | 0 | 8 | 8 | 8 | |
| 4 | 0 | 7 | 8 | 7 | 10 | 8 | 8 | 8 | |
| 6 | 2 | 16 | 10 | 16 | 8 | 8 | 11 | 12 | |
| DMSO | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Fluconazole | 0 | 0 | 0 | 6 | 0 | 0 | 0 | - - - - - | - - - - |
| Ciprofloxacin | - - - - - | - - - - | - - - - - | - - - - | - - - - - | - - - - | - - - - - | 32 | 32 |
Fig. 6Antibacterial activity of synthesized coumarin compounds (1–10).
Fig. 7Antifungal activity of synthesized coumarin compounds (1–10).
Fig. 8In vitro antimicrobial activity of target coumarin compounds (1–10).
Docking study data of compounds (1–10) showing the binding energy between ligands and enzymes.
| Compound name | 2vf5 (GlcN-6-P synthase) | 3jus (lanosterol 14α-demethylase (CYP51) Δ | 3juv (lanosterol 14α-demethylase (CYP51) Δ |
|---|---|---|---|
| -42.26 | -15.67 | -23.42 | |
| -26.13 | -14.38 | -14.53 | |
| -25.53 | -18.22 | -13.35 | |
| -39.86 | -20.05 | -16.26 | |
| -27.63 | -12.53 | -12.82 | |
| -26.79 | -13.13 | -13.33 | |
| -24.50 | -12.79 | -13.88 | |
| -40.08 | -16.25 | -14.62 | |
| -11.09 | -11.04 | -10.69 | |
| -26.40 | -15.05 | -11.46 |